NCT07533942
A Study of JZP3507 (ONC206) in Recurrent Grade 2 or 3 Meningioma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Eligibility criteria expanded, about 32 words
- Trial sites expanded: 5 → 8 locations
- Secondary endpoints: details revised at 2 of 13 entries
- Notable Recruitment opened
- Start date changed from estimate of Jun 1, 2026 to Jul 16, 2026
- Secondary endpoints: details revised at 13 of 13 entries
- Site details revised at 5 of 5 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Overall Response Rate (ORR) as Assessed by Response Assessment in Neuro-Oncology (RANO) Criteria and Evaluated by Blinded Independent Central Review (BICR)
Timeframe: From first dose until death, withdrawal of consent, or lost to follow-up, up to 36 months.
Secondary (13)
Duration of Response (DOR)
Time to Response (TTR)
Disease Control Rate (DCR)
Progression-Free Survival (PFS)
Overall Survival (OS)
Show 8 moreShow less
Incidence of Grade 3 or higher Treatment-Emergent Adverse Events (TEAEs)
Number of Adverse Events (AEs) Resulting in Study Discontinuation
Maximum Observed Plasma Concentration (Cmax) of JZP3507
Time of Maximum Observed Plasma Concentration (Tmax) of JZP3507
Area Under the Concentration-Time Curve Over a Time interval (AUC(0-τ)) of JZP3507
Terminal Elimination Half-life ( t½) of JZP3507
Apparent Oral Clearance (CL/F)
Apparent Volume of Distribution After Oral Dose (Vz/F)
Arms and interventions
JZP3507 (ONC206)Experimental
Drugs: JZP3507
Sites
8 sites in 1 country